semaglutide
Tirzepatide vs Semaglutide: 30% Death Reduction?
Tirzepatide is linked to a 30% lower all-cause death risk than semaglutide over three years, according to a national registry. The finding reshapes how we weigh long-term safety when prescribing GLP-1 receptor agonists for obesity. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice.